助阳宁神方拮抗应激致抑郁小鼠海马星形胶质细胞可塑性损伤的作用研究
|
摘要
研究目的
依据中医临床“助阳入脑,降火宁神”的治疗抑郁症的新思想创制助阳宁神方,该方在临床上确具较好疗效。研究发现其作用机制可能不是通过影响单胺类神经递质而产生,而可能与星形胶质细胞可塑性改变有关。为此,本课题采用皮质酮注射制备抑郁动物模型,从非单胺类神经递质假说中的星形胶质细胞可塑性入手,观察应激和助阳宁神方(Zhuyang-ningshen Formula, ZNF)作用前后星形胶质细胞可塑性变化：包括GFAP蛋白的表达改变、星形胶质细胞形态、数量等,期望探究助阳宁神方在该模型的效应,阐明调节海马星形胶质细胞可塑性是助阳宁神方临床改善抑郁症的作用机制,从而使“助阳入脑,降火宁神”思想得到实验证实,为抑郁症防治和新药研发提供科学的实验理论依据。
研究方法
(1)助阳宁神方药效学研究
采用利血平拮抗模型观察小鼠闭眼率；5-羟色氨酸(5-hydroxytryptophane,5-HTP)诱导的甩头行为模型观测甩头率及甩头次数；育亨宾毒性模型观测各组小鼠死亡率；悬尾实验观测行为学改变。
(2)抑郁小鼠模型制备及助阳宁神方抗抑郁有效性验证实验研究
皮质酮皮下注射制备抑郁动物模型,实验分为6组,分别是正常组、模型组、氟西汀组,助阳宁神方低剂量组(1.9g/kg)、中剂量组(3.8g/kg)和高剂量组(7.6g/kg),每组8只,共48只C57BL/6N小鼠；采用强迫游泳、强迫悬尾观察给药4周后小鼠行为学改变和体重变化,然后处死动物,快速取脑剥离海马,Western blot蛋白免疫印迹检测神经元NF-L、SY-P蛋白表达变化,同时,观测助阳宁神方对该模型的拮抗作用。
(3)基于星形胶质细胞可塑性的助阳宁神方抗抑郁作用机制研究
实验分6组,分别是正常组、模型组、氟西汀组,助阳宁神方低剂量组(1.9g/kg)、中剂量组(3.8g/kg)和高剂量组(7.6g/kg),每组12只C57BL/6N小鼠,共72只小鼠。给药4周后,采用Western blot及免疫组化技术观测海马胶质纤维酸性蛋白(GFAP)、BDNF和GDNF表达改变,体视学分析技术检测海马GFAP表达阳性细胞数。
研究结果
(1)助阳宁神方药效学研究结果
1)利血平拮抗模型
与模型组闭眼率100%比,氟西汀组闭眼率为30%,闭眼率显著降低(P<0.01),助阳宁神方高、中、低剂量组闭眼率依次为60%、50%、40%,闭眼率也显著性降低(P<0.05、P<0.05、P<0.01),与氟西汀组比,助阳宁神方高、中、低剂量组闭眼率随剂量下降,闭眼率逐渐下降,但无显著性差异(P>0.05)。
2)5-HTP诱导的甩头行为模型
连续给药第3天、第7天15min后,正常组、氟西汀组、助阳宁神方高、中、低剂量组甩头率分别为：40%、80%、50%、40%和30%；40%、90%、40%、30%和20%,与正常组比,氟西汀组甩头率明显增加(P<0.01),而ZNF高、中、低剂量组均未增加甩头率(P均>0.05)；与氟西汀组比,ZNF高、中、低剂量组均甩头率显著下降(P<0.01)；第7天15min后,各相应组甩头次数依次为70次、246次、53次、27次和34次；ZNF各组甩头次数与正常组比无显著上升(P均>0.05)。
3)育亨宾毒性模型
正常组、氟西汀组、ZNF高、中、低剂量组死亡小鼠依次为1只、5只、2只、1只、1只,与正常组比,氟西汀组小鼠死亡率显著升高(P<0.01),而ZNF各组小鼠死亡率未显著上升(P>0.05),与氟西汀组比,ZNF各组小鼠死亡率显著下降(P均<0.01)。
4)悬尾实验
与正常组比,氟西汀组、ZNF高、中、低剂量组悬尾不动时间显著缩短(p<0.01或p<0.05)。
(2)皮质酮致抑郁小鼠模型建立及助阳宁神方有效性验证实验结果
1)体重变化结果
各实验组起始体重无显著性差异(P均>0.05),4周后,模型组动物较正常组动物体重明显减轻(P<0.05),但其他各组与模型组比,均具有上调体重趋势,但无统计学意义(P均>0.05)。
2)行为学实验研究结果
在悬尾实验、强迫游泳中,与正常组比,模型组不动时间明显延长(P<0.01,P<0.05),与模型组比,氟西汀组不动时间明显缩短(P<0.01,P<0.05),助阳宁神方中((P<0.01,P<0.05)、低剂量组(P均<0.05)不动时间也显著缩短,助阳宁神方高剂量组不动时间未见显著缩短(P>0.05)。
3) westem blot免疫印迹实验结果
与正常组比,模型组NF-L、SYP表达水平著下降(P<0.01、P<0.05)；与模型组比,氟西汀组NF-L、SYP表达水平显著上调(P<0.01、P<0.05),助阳宁神方高、中、低剂量组均能明显上调NF-L、SYP表达水平(P均<0.05)。
(3)基于星形胶质细胞可塑性的助阳宁神方抗抑郁作用机制研究结果
1) westem blot免疫印迹实验结果
与正常组比,模型组GFAP、BDNF及GDNF的表达较正常组水平著下调(P<0.01、P<0.01、P<0.01),与模型组比,氟西汀组除GDNF未见显著上调外,其他指标均显著著上调(P<0.05或P<0.01),助阳宁神方中、低剂量组均能显著上调GFAP、BDNF及GDNF的蛋白表达水平(P<0.05或P<0.01),而ZNF高剂量组显著上调GFAP及GDNF (P<0.05或P<0.01),而对BDNF却无显著上调作用(P>0.05)。
2)免疫组化表达结果
在海马CA3区和CA1区,与正常组比,模型组GFAP阳性区域总光密度值和面积均明显下调(P<0.05或P<0.01),与模型组比,氟西汀组、助阳宁神方高、中、低剂量组均能显著上调GFAP阳性区域总光密度值(P<0.05或P<0.01)；在CA3区助阳宁神方高、中剂量组及在CA1区助阳宁神方中剂量组GFAP阳性表达区域面积明显上调(P<0.05或P<0.01)；在DG区,氟西汀组、助阳宁神方高、中、低剂量组GFAP阳性表达区域总光密度值显著上调(P<0.05或P<0.01),但GFAP阳性表达区域面积均无明显上调(P>0.05)。
3)体视学分析结果
与正常组比,模型组海马GFAP阳性细胞(星形胶质细胞)个数显著下调(P<0.05),与模型组比,氟西汀组、ZNF高、中剂量组能显著上调GFAP阳性细胞(P<0.05、P<0.01、P<0.05),ZNF低剂量组有上调GFAP阳性细胞的趋势(P>0.05)。
结论
(1)助阳宁神方具有抗抑郁样行为作用；
(2)助阳宁神方抗抑郁作用可能不是通过影响单胺类神经递质产生；
(3)助阳宁神方可能通过上调星形胶质细胞可塑性、神经可塑性、增加神经营养因子对神经元的损伤修复,改善海马可塑性,进而发挥抗抑郁作用。
Objective
Based on the new TCM idea of "zhu yang ru nao, jiang huo ning shen", the formula of "zhu yang ning shen" was developed,which showed good curative effects on depression in clinic. We found that the underlying mechanisms might be associated with the astroglia plasticity instead of the monoamine transmitters. In this project, we will adopt corticosterone-induced animal model of depression, and observed effects of the formula on the downregulation of astroglia plasticity in the hippocampus of model animals (e.g. the number of astroglia and the expression of GFAP).Through above experimental design, we hope that we can prove the crucial role of astroglia plasticy improvement in the treatment of the "zhu yang ning shen" formula on depression, which will contribute to illustrate the value of the new TCM idea in the treatment of depression in clinic and the development of new antidepressants from the aspect of astroglia.
Methods
(1) Study on pharmacodynamics of Zhuyang-ningshen Formula(ZNF)
Reserpine antagonistic model in mice was observed with eyes closed rate;The head-witching test models were established by injection of5-HTP,the rate and the number of head-witching were tested; Yohimbine toxicity model was uesd to observe the mortality of mice; tail suspension test were observed behavior change.
(2) Preparation of mice depression model induced by corticosterone and antidepressive validation experiment of Zhuyang-ningshen Formula
Mice depression model was developed by subcutaneous injection of corticosterone in48C57BL/6N, which were equally devided into6groups of model control, F(treated with fiuoxetine hydrochloride3.6mg/kg), ZNF1(treated with gastric gavage of ZNF1.9g/kg),ZNF2(treated with ZNF3.8g/kg), ZNF3(treated with ZNF7.6g/kg);4weeks later, observed behavior change by forced swimming test and tail suspension test and weight chang,then the mice were sacrificed by decapitation and the hippocampal tissues were rapidly collected for western blot analysis of neurofliament light chain protein(NF-L) and synaptic vescle protein(SYP), at the same time, the antagonistic effects of Zhuyang-ningshen Formula also were observed.
(3) Antidepressive mechanism of Zhuyang-ningshen Formula on hippocampal astrocyte plasticity
Mice depression model was developed by subcutaneous injection of corticosterone in72C57BL/6N, which were equally devided into6groups of model control, F(treated with fiuoxetine hydrochloride3.6mg/kg), ZNF1(treated with gastric gavage of ZNF1.9g/kg), ZNF2(treated with ZNF3.8g/kg), ZNF3(treated with ZNF7.6g/kg); After drug delivery4weeks, we dectected the protein lever of GFAP and BDNF and GDNF with western blot, counted hippocampal GFAP positive cells by steorology analysis system.
Results
(1) Pharmacodynamics research of Zhuyang-ningshen Formula results
1) In the reserpine antagonistic model, eyes closed rate of model control group,F(treated with fiuoxetine hydrochloride)group, ZNF1(treated with gastric gavage of ZNF1.9g/kg), ZNF2(treated with ZNF3.8g/kg), ZNF3(treated with ZNF7.6g/kg) each was100%,30%,60%,50%and40%, compared with model control group, eyes closed rate of F group and ZNF1and ZNF2and ZNF3was remarkable decreased (P<0.01, P<0.05、P<0.05、P<0.01); In comparison with F group, it was decreased to all dosage of ZNF,at the same time, as the dose increased,the eyes closed rate was stepped up,but no significant difference(P>0.05); In all dose of ZNF(P<0.01), no significant difference in each ZNF groups(P>0.05).
2) In the head-switching test model by injection of5-HTP, the rate of head-switching behavior on the3rd and7th day15min after drug delivery each was40%,80%,50%,40%,30%and40%,90%,40%,30%,20%,the number of head-switching behavior was70,246,53,27and34,respectively, the rate of head-switching was higher in F group than that in normal group(P<0.01), but no significantly Increased in each ZNF,compared with F group, there was notable descended(P<0.01),and so for the number of head-switching behavior.
3) In the yohimbine toxicity model, mouse death number each was1,5,2,1,1,the mortality rate of was higher in F group than that in normal group(P<0.01)and in all dose of ZNF(P<0.01), but no outstanding increased in each ZNF groups(P>0.05).
4) In tail suspension test, compared of normal group, immobility time were noticeable shortened in F group (P<0.01) and ZNF1group(P<0.05) and ZNF2group(P<0.05) and ZNF3group (P<0.05).
(2) Preparation of mice depression model induced by corticosterone and antidepressive validation experiment of Zhuyang-ningshen Formula
1) Results of weight change
There was no significant difference between the initial weight in each experimental group(P>0.05).Four weeks later, there was striking weight loss in model group than in normal groups(P<0.05), but if compared with model group,other groups had raised the weight trend, but no statistical significance(P>0.05).
2) Results of behavior experimental study
Compared of normal group,immobility time in tail suspension test and in forced swimming of model group were noticeable lengthened (P<0.01,P<0.05); in comparison with the model group, immobility time were eminent shortened in F group (P<0.01,P<0.05) and ZNF2group(P<0.01,P<0.05) and ZNF3group(P<0.05),but no reduced immobility time in ZNF1group (P>0.05)
3) Results of western blot
Compared of normal group, the protein level of NF-L and SYP were conspicuous down-regulationed in the model group (P<0.01,P<0.05), in comparison with the model group, the protein level of NF-L and SYP were noticeable up-regulated in F group (P<0.01,P<0.05) and in ZNF1,ZNF2and ZNF3(P<0.05).
(3) Antidepressive mechanism of Zhuyang-ningshen Formula on hippocampal astrocyte plasticity
1) Mechanism of antidepressant action results of Zhuyang-ningshen Formula on hippocampal astrocyte plasticity
In comparison with normal group, the protein level of GFAP and BDNF and GDNF were conspicuous down-regulated in the model group(P<0.01, P<0.01and P<0.01),compared with the model group, the expression level of GFAP and BDNF were clearly increased(P<0.05,P<0.01), the expression level of GDNF only had a little increasion, but no distinct difference(P>0.05),the expression level of GFAP and BDNF and GDNF were up-regulated in ZNF2and ZNF3(P<0.05or P<0.01),but in ZNF1only could up-regulated GFAP and GDNF(P<0.05or P<0.01),there was no noticeably went up in the expression of BDNF(P>0.05).
2) Results of immunohistochemical expression
In the hippocampal CA3region and CA1region, in comparison with normal group, positive regional total optical density value and positive region with a total area of GFAP in model group, decreased obviously(P<0.05or P<0.01),compared with the model group,there were clear up about positive regional total optical density value of GFAP in the F,ZNF1,ZNF2and ZNF3(P<0.05or P<0.01); In the hippocampal CA3region,ZNF1and ZNF2could up-regulated positive region with a total area of GFAP, so did ZNF2in the hippocampal CA1region (P<0.05or P<0.01); In the hippocampal DG region, positive regional total optical density value of GFAP were up-regulated in the group of F,ZNF1,ZNF2and ZNF3(P<0.05or P<0.01),but there was no significant risen about positive region with a total area of GFAP(P>0.05).
3) Results of steorology
Compared with the normal group,the number of the GFAP positive cells (astrocyte)in hippocampus in Model group,was decreased,in comparison with model group,the number of the GFAP positive cells were increased obveriously in fluoxetine group, high dose group and middle dose group of Zhuyang-ningshen formula (P<0.05、P<0.01、P<0.05), but low dose group of Zhuyang-ningshen formula only had an uptrend of increasing the number of the GFAP positive cells (P>0.05).
Conclusion:(1) Zhuyang-ningshen Formula have the effect of antagonism on the action of depression.
(2) Antidepressive effect of Zhuyang-ningshen Formula may not affect monoamine neurotransmitter.
(3) Zhuyang-ningshen Formula may up-regulate astrocyte plasticity, enhancement of neurotrophic factor on neuronal injury and repair, improve hippocampal plasticity, exert antidepressant effects.
依据中医临床“助阳入脑,降火宁神”的治疗抑郁症的新思想创制助阳宁神方,该方在临床上确具较好疗效。研究发现其作用机制可能不是通过影响单胺类神经递质而产生,而可能与星形胶质细胞可塑性改变有关。为此,本课题采用皮质酮注射制备抑郁动物模型,从非单胺类神经递质假说中的星形胶质细胞可塑性入手,观察应激和助阳宁神方(Zhuyang-ningshen Formula, ZNF)作用前后星形胶质细胞可塑性变化：包括GFAP蛋白的表达改变、星形胶质细胞形态、数量等,期望探究助阳宁神方在该模型的效应,阐明调节海马星形胶质细胞可塑性是助阳宁神方临床改善抑郁症的作用机制,从而使“助阳入脑,降火宁神”思想得到实验证实,为抑郁症防治和新药研发提供科学的实验理论依据。
研究方法
(1)助阳宁神方药效学研究
采用利血平拮抗模型观察小鼠闭眼率；5-羟色氨酸(5-hydroxytryptophane,5-HTP)诱导的甩头行为模型观测甩头率及甩头次数；育亨宾毒性模型观测各组小鼠死亡率；悬尾实验观测行为学改变。
(2)抑郁小鼠模型制备及助阳宁神方抗抑郁有效性验证实验研究
皮质酮皮下注射制备抑郁动物模型,实验分为6组,分别是正常组、模型组、氟西汀组,助阳宁神方低剂量组(1.9g/kg)、中剂量组(3.8g/kg)和高剂量组(7.6g/kg),每组8只,共48只C57BL/6N小鼠；采用强迫游泳、强迫悬尾观察给药4周后小鼠行为学改变和体重变化,然后处死动物,快速取脑剥离海马,Western blot蛋白免疫印迹检测神经元NF-L、SY-P蛋白表达变化,同时,观测助阳宁神方对该模型的拮抗作用。
(3)基于星形胶质细胞可塑性的助阳宁神方抗抑郁作用机制研究
实验分6组,分别是正常组、模型组、氟西汀组,助阳宁神方低剂量组(1.9g/kg)、中剂量组(3.8g/kg)和高剂量组(7.6g/kg),每组12只C57BL/6N小鼠,共72只小鼠。给药4周后,采用Western blot及免疫组化技术观测海马胶质纤维酸性蛋白(GFAP)、BDNF和GDNF表达改变,体视学分析技术检测海马GFAP表达阳性细胞数。
研究结果
(1)助阳宁神方药效学研究结果
1)利血平拮抗模型
与模型组闭眼率100%比,氟西汀组闭眼率为30%,闭眼率显著降低(P<0.01),助阳宁神方高、中、低剂量组闭眼率依次为60%、50%、40%,闭眼率也显著性降低(P<0.05、P<0.05、P<0.01),与氟西汀组比,助阳宁神方高、中、低剂量组闭眼率随剂量下降,闭眼率逐渐下降,但无显著性差异(P>0.05)。
2)5-HTP诱导的甩头行为模型
连续给药第3天、第7天15min后,正常组、氟西汀组、助阳宁神方高、中、低剂量组甩头率分别为：40%、80%、50%、40%和30%；40%、90%、40%、30%和20%,与正常组比,氟西汀组甩头率明显增加(P<0.01),而ZNF高、中、低剂量组均未增加甩头率(P均>0.05)；与氟西汀组比,ZNF高、中、低剂量组均甩头率显著下降(P<0.01)；第7天15min后,各相应组甩头次数依次为70次、246次、53次、27次和34次；ZNF各组甩头次数与正常组比无显著上升(P均>0.05)。
3)育亨宾毒性模型
正常组、氟西汀组、ZNF高、中、低剂量组死亡小鼠依次为1只、5只、2只、1只、1只,与正常组比,氟西汀组小鼠死亡率显著升高(P<0.01),而ZNF各组小鼠死亡率未显著上升(P>0.05),与氟西汀组比,ZNF各组小鼠死亡率显著下降(P均<0.01)。
4)悬尾实验
与正常组比,氟西汀组、ZNF高、中、低剂量组悬尾不动时间显著缩短(p<0.01或p<0.05)。
(2)皮质酮致抑郁小鼠模型建立及助阳宁神方有效性验证实验结果
1)体重变化结果
各实验组起始体重无显著性差异(P均>0.05),4周后,模型组动物较正常组动物体重明显减轻(P<0.05),但其他各组与模型组比,均具有上调体重趋势,但无统计学意义(P均>0.05)。
2)行为学实验研究结果
在悬尾实验、强迫游泳中,与正常组比,模型组不动时间明显延长(P<0.01,P<0.05),与模型组比,氟西汀组不动时间明显缩短(P<0.01,P<0.05),助阳宁神方中((P<0.01,P<0.05)、低剂量组(P均<0.05)不动时间也显著缩短,助阳宁神方高剂量组不动时间未见显著缩短(P>0.05)。
3) westem blot免疫印迹实验结果
与正常组比,模型组NF-L、SYP表达水平著下降(P<0.01、P<0.05)；与模型组比,氟西汀组NF-L、SYP表达水平显著上调(P<0.01、P<0.05),助阳宁神方高、中、低剂量组均能明显上调NF-L、SYP表达水平(P均<0.05)。
(3)基于星形胶质细胞可塑性的助阳宁神方抗抑郁作用机制研究结果
1) westem blot免疫印迹实验结果
与正常组比,模型组GFAP、BDNF及GDNF的表达较正常组水平著下调(P<0.01、P<0.01、P<0.01),与模型组比,氟西汀组除GDNF未见显著上调外,其他指标均显著著上调(P<0.05或P<0.01),助阳宁神方中、低剂量组均能显著上调GFAP、BDNF及GDNF的蛋白表达水平(P<0.05或P<0.01),而ZNF高剂量组显著上调GFAP及GDNF (P<0.05或P<0.01),而对BDNF却无显著上调作用(P>0.05)。
2)免疫组化表达结果
在海马CA3区和CA1区,与正常组比,模型组GFAP阳性区域总光密度值和面积均明显下调(P<0.05或P<0.01),与模型组比,氟西汀组、助阳宁神方高、中、低剂量组均能显著上调GFAP阳性区域总光密度值(P<0.05或P<0.01)；在CA3区助阳宁神方高、中剂量组及在CA1区助阳宁神方中剂量组GFAP阳性表达区域面积明显上调(P<0.05或P<0.01)；在DG区,氟西汀组、助阳宁神方高、中、低剂量组GFAP阳性表达区域总光密度值显著上调(P<0.05或P<0.01),但GFAP阳性表达区域面积均无明显上调(P>0.05)。
3)体视学分析结果
与正常组比,模型组海马GFAP阳性细胞(星形胶质细胞)个数显著下调(P<0.05),与模型组比,氟西汀组、ZNF高、中剂量组能显著上调GFAP阳性细胞(P<0.05、P<0.01、P<0.05),ZNF低剂量组有上调GFAP阳性细胞的趋势(P>0.05)。
结论
(1)助阳宁神方具有抗抑郁样行为作用；
(2)助阳宁神方抗抑郁作用可能不是通过影响单胺类神经递质产生；
(3)助阳宁神方可能通过上调星形胶质细胞可塑性、神经可塑性、增加神经营养因子对神经元的损伤修复,改善海马可塑性,进而发挥抗抑郁作用。
Objective
Based on the new TCM idea of "zhu yang ru nao, jiang huo ning shen", the formula of "zhu yang ning shen" was developed,which showed good curative effects on depression in clinic. We found that the underlying mechanisms might be associated with the astroglia plasticity instead of the monoamine transmitters. In this project, we will adopt corticosterone-induced animal model of depression, and observed effects of the formula on the downregulation of astroglia plasticity in the hippocampus of model animals (e.g. the number of astroglia and the expression of GFAP).Through above experimental design, we hope that we can prove the crucial role of astroglia plasticy improvement in the treatment of the "zhu yang ning shen" formula on depression, which will contribute to illustrate the value of the new TCM idea in the treatment of depression in clinic and the development of new antidepressants from the aspect of astroglia.
Methods
(1) Study on pharmacodynamics of Zhuyang-ningshen Formula(ZNF)
Reserpine antagonistic model in mice was observed with eyes closed rate;The head-witching test models were established by injection of5-HTP,the rate and the number of head-witching were tested; Yohimbine toxicity model was uesd to observe the mortality of mice; tail suspension test were observed behavior change.
(2) Preparation of mice depression model induced by corticosterone and antidepressive validation experiment of Zhuyang-ningshen Formula
Mice depression model was developed by subcutaneous injection of corticosterone in48C57BL/6N, which were equally devided into6groups of model control, F(treated with fiuoxetine hydrochloride3.6mg/kg), ZNF1(treated with gastric gavage of ZNF1.9g/kg),ZNF2(treated with ZNF3.8g/kg), ZNF3(treated with ZNF7.6g/kg);4weeks later, observed behavior change by forced swimming test and tail suspension test and weight chang,then the mice were sacrificed by decapitation and the hippocampal tissues were rapidly collected for western blot analysis of neurofliament light chain protein(NF-L) and synaptic vescle protein(SYP), at the same time, the antagonistic effects of Zhuyang-ningshen Formula also were observed.
(3) Antidepressive mechanism of Zhuyang-ningshen Formula on hippocampal astrocyte plasticity
Mice depression model was developed by subcutaneous injection of corticosterone in72C57BL/6N, which were equally devided into6groups of model control, F(treated with fiuoxetine hydrochloride3.6mg/kg), ZNF1(treated with gastric gavage of ZNF1.9g/kg), ZNF2(treated with ZNF3.8g/kg), ZNF3(treated with ZNF7.6g/kg); After drug delivery4weeks, we dectected the protein lever of GFAP and BDNF and GDNF with western blot, counted hippocampal GFAP positive cells by steorology analysis system.
Results
(1) Pharmacodynamics research of Zhuyang-ningshen Formula results
1) In the reserpine antagonistic model, eyes closed rate of model control group,F(treated with fiuoxetine hydrochloride)group, ZNF1(treated with gastric gavage of ZNF1.9g/kg), ZNF2(treated with ZNF3.8g/kg), ZNF3(treated with ZNF7.6g/kg) each was100%,30%,60%,50%and40%, compared with model control group, eyes closed rate of F group and ZNF1and ZNF2and ZNF3was remarkable decreased (P<0.01, P<0.05、P<0.05、P<0.01); In comparison with F group, it was decreased to all dosage of ZNF,at the same time, as the dose increased,the eyes closed rate was stepped up,but no significant difference(P>0.05); In all dose of ZNF(P<0.01), no significant difference in each ZNF groups(P>0.05).
2) In the head-switching test model by injection of5-HTP, the rate of head-switching behavior on the3rd and7th day15min after drug delivery each was40%,80%,50%,40%,30%and40%,90%,40%,30%,20%,the number of head-switching behavior was70,246,53,27and34,respectively, the rate of head-switching was higher in F group than that in normal group(P<0.01), but no significantly Increased in each ZNF,compared with F group, there was notable descended(P<0.01),and so for the number of head-switching behavior.
3) In the yohimbine toxicity model, mouse death number each was1,5,2,1,1,the mortality rate of was higher in F group than that in normal group(P<0.01)and in all dose of ZNF(P<0.01), but no outstanding increased in each ZNF groups(P>0.05).
4) In tail suspension test, compared of normal group, immobility time were noticeable shortened in F group (P<0.01) and ZNF1group(P<0.05) and ZNF2group(P<0.05) and ZNF3group (P<0.05).
(2) Preparation of mice depression model induced by corticosterone and antidepressive validation experiment of Zhuyang-ningshen Formula
1) Results of weight change
There was no significant difference between the initial weight in each experimental group(P>0.05).Four weeks later, there was striking weight loss in model group than in normal groups(P<0.05), but if compared with model group,other groups had raised the weight trend, but no statistical significance(P>0.05).
2) Results of behavior experimental study
Compared of normal group,immobility time in tail suspension test and in forced swimming of model group were noticeable lengthened (P<0.01,P<0.05); in comparison with the model group, immobility time were eminent shortened in F group (P<0.01,P<0.05) and ZNF2group(P<0.01,P<0.05) and ZNF3group(P<0.05),but no reduced immobility time in ZNF1group (P>0.05)
3) Results of western blot
Compared of normal group, the protein level of NF-L and SYP were conspicuous down-regulationed in the model group (P<0.01,P<0.05), in comparison with the model group, the protein level of NF-L and SYP were noticeable up-regulated in F group (P<0.01,P<0.05) and in ZNF1,ZNF2and ZNF3(P<0.05).
(3) Antidepressive mechanism of Zhuyang-ningshen Formula on hippocampal astrocyte plasticity
1) Mechanism of antidepressant action results of Zhuyang-ningshen Formula on hippocampal astrocyte plasticity
In comparison with normal group, the protein level of GFAP and BDNF and GDNF were conspicuous down-regulated in the model group(P<0.01, P<0.01and P<0.01),compared with the model group, the expression level of GFAP and BDNF were clearly increased(P<0.05,P<0.01), the expression level of GDNF only had a little increasion, but no distinct difference(P>0.05),the expression level of GFAP and BDNF and GDNF were up-regulated in ZNF2and ZNF3(P<0.05or P<0.01),but in ZNF1only could up-regulated GFAP and GDNF(P<0.05or P<0.01),there was no noticeably went up in the expression of BDNF(P>0.05).
2) Results of immunohistochemical expression
In the hippocampal CA3region and CA1region, in comparison with normal group, positive regional total optical density value and positive region with a total area of GFAP in model group, decreased obviously(P<0.05or P<0.01),compared with the model group,there were clear up about positive regional total optical density value of GFAP in the F,ZNF1,ZNF2and ZNF3(P<0.05or P<0.01); In the hippocampal CA3region,ZNF1and ZNF2could up-regulated positive region with a total area of GFAP, so did ZNF2in the hippocampal CA1region (P<0.05or P<0.01); In the hippocampal DG region, positive regional total optical density value of GFAP were up-regulated in the group of F,ZNF1,ZNF2and ZNF3(P<0.05or P<0.01),but there was no significant risen about positive region with a total area of GFAP(P>0.05).
3) Results of steorology
Compared with the normal group,the number of the GFAP positive cells (astrocyte)in hippocampus in Model group,was decreased,in comparison with model group,the number of the GFAP positive cells were increased obveriously in fluoxetine group, high dose group and middle dose group of Zhuyang-ningshen formula (P<0.05、P<0.01、P<0.05), but low dose group of Zhuyang-ningshen formula only had an uptrend of increasing the number of the GFAP positive cells (P>0.05).
Conclusion:(1) Zhuyang-ningshen Formula have the effect of antagonism on the action of depression.
(2) Antidepressive effect of Zhuyang-ningshen Formula may not affect monoamine neurotransmitter.
(3) Zhuyang-ningshen Formula may up-regulate astrocyte plasticity, enhancement of neurotrophic factor on neuronal injury and repair, improve hippocampal plasticity, exert antidepressant effects.
引文
[1]Zhao YN, Xie WD, Dai JG, et al. The varying effects of short-tem and long-term corticosterone injections on depression-like behavior in mice[J]. Brain Res 2009,1261:82-90
[2]Gronli J, Bramham C, Murison R, et al. Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper. Pharmacol Biochem Behav 2006,85:842-849
[3]Berton 0, Nestler EJ. New approaches to antidepressant drug discovery:beyond monoamines. Nature Rev Neurosci 2006,7:137-151
[4]薛瑞,张有志,邹莉波.快速起效抗抑郁药物的研究进展[J].中国药理学通报,2006,24(12)：1558-1561.
[5]楼剑书,杨晓春,方杰,等.免疫激活对抑郁症谷氨酸和五羟色胺系统的调节[J].中国药理学通报,2009,25(12)：1555-1558
[6]张敬军.星形胶质细胞的研究[J].中国药理学通报,2006,22(7)：788-791
[7]He F, Sun Y E. Glial cells more than support cell[J]? Int J Biochem Cell B iol,2007,39 (4):661-665.
[8]Kimelberg HK. The role of hypotheses in current research, illustrated by hypotheses on the possible role of astrocytes in energy metabolism and cerebral blood flow:from Newton to now [J]. J. Cereb. Blood Flow Metab,2004, 24:1235-1239
[9]Tekkok SB, Brown AM, Westenbrock R, et al. Transfer of glycogen-derived lactate from astrocytes to axons via specific monocarboxylate transporters supports mouse optic nerve activity. J. Neurosci. Res.2005,81:644-652
[10]Koudinov AR, Koudinova NV. Cholesterol's role in synapse formation[J]. Science,2002; 295(5563):2213
[11]Miller G. Society for neuroscience meeting:neurons get connected via glia[J]. Science,2003; 302:1323-1323
[12]Murai KK, Nguye LN, Irie F, et al. Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling[J]. Nat Neurosci,2002,6: 153-160
[13]Song HJ, Stevens CF, Gage FH. Neural Stem Cells from Adult Hippocampus Develop Essential Properties of Functional CNS Neurons[J]. Nat Neurosci, 2002,5 (5):438-445
[14]Williams SM, Diaz CM, Macnab LT, et al. Immunocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons[J]. Glia 2006,53:401-411
[15]Verrall L, Walker M, Rawlings N, et al. D-amino acid oxidase and serine racemase in human brain:normal distribution and altered expression in schizophrenia[J]. Eur. J. Neurosci.2007,26:1657-1669
[16]Czeh B, Simon M, Schmelting B, et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment[J]. Neuropsychopharmacology,2006,31:1616-1626.
[17]Si X, Miguel-Hidalgo JJ,O'Dwyer G, et al. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression[J]. Neuropsychopharmacology 2004,29:2088-2096
[18]Webster MJ,O'Grady J, Kleinman JE, et al. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia[J]. Neuroscience 2005,133:453-461
[19]Leventopoulos M, Ruedi-Bettschen D, Knuesel I, et al. Long-term effects of early life deprivation on brain glia in Fischer rats[J]. Brain Res,2007, 1142:119-126
[20]Gosselin RD, Gibney S,O'Malley D, et al. Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression[J]. Neuroscience 2009,159:915-925
[21]Czeh B, Simon M, Schmelting B, et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment[J]. Neuropsychopharmacology2006,31:1616-1626
[22]Banasr M, Chowdhury G. M, Terwi 11 iger R, et al. Glial pathology in an animal model of depression:reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole[J]. Mol. Psychiatry, e-pub ahead of print 30 September 2008; doi:10.1038/mp.2008.106.
[23]Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressivc-like behaviors. Biol. Psychiatry,2008,64:863-870
[24]陈红霞,张黎明,张有志,等.胍丁胺对慢性应激人鼠海马神经元和星形胶质细胞的影响[J].中国药理学通报,2009,25(1)：21-25
[24]Chen HX, Zhang LM, Zhang YZ,et al. Effect of agmatine on the neurons and astrocytes in hippocampus of chronically stressed rats[J]. Chin Pharmacol Bull,2009,25 (1):21-25
[25]Liu Q, Li B, Zhu HY, et al. Clomipramine treatment reversed the glial pathology in a chronic unpredictable stress-induced rat model of depression[J]. Eur Neuropsychopharmacol,2009,19:796-805
[26]Rose C. Effect of ammonia on astrocytic glutamate uptake/release mechanisms[J]. J Neurochem,2006,97:11-15
[27]Ozawa S. Role of glutamate transporters in excitatory synapses in cerebellar Purkinje cells[J]. Brain Nerve,2007,59:669F-676
[28]Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA. Reduced expression of glutamate transporters vGluTl, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression[J]. Neuropharmacology,2010,58(2):465-473
[29]郭坤萌,周唯.抑郁症辨证论治述要[J].山东中医杂志2011,30(2)：77-78
[30]鱼浚镛,田金洲.试述中医对抑郁症的认识[J].天津中医药2011,28(4)：343-345
[31]华燕.抑郁症的诊断及中医辨证论治[J].辽宁中医药大学学报2011,13(10)：17-18
[32]毕国伟,卢政男,江泳.抑郁症发病的基础病机之论阳气不足论[J].成都中医药大学学报2011,34(3)：88-90
[33]包祖晓,田青,陈宝君,钟宇峰,李黎.抑郁症与中医阳气亏虚证关系的探讨[J].浙江中医药大学学报2011,35(3)：466-467
[34]冼慧,清华.抑郁症的中医辨治[J].北京中医,2007,26(3)：136-137
[35]赵晶.抑郁症从脾论治[J].吉林中医药,2011,31(6)：506-507
[36]陈文铠,周玲,梅晓云,彭昌孝,李国春,黄云,陈文姬,彭计红.从临床流行病学调查探讨抑郁症中医病机规律[J].南京中医药大学学报2005,21(5)：273-276.
[37]张有为,谢忠礼.抑郁症中医病因病机探讨[J].中医学报2010,25(148)：435-436.
[38]张昶,谭程.抑郁症从奇经论治浅析[J].北京中医药2010,29(3)：196-198.
[39]姜林芳,方习红.王法德辨治抑郁症经验[J].中医杂志2010,51(6)：495,509.
[40]杨小青,张小玲.从中医“情志致病”探讨抑郁症成因[J].辽宁中医药大学学报2010,12(9)：87-88
[41]宋通贵,孙萍,张燕,等.中医辨证论治抑郁症的探讨[J].中国实用医药2009,4(25)：220-221
[42]杨耀峰,刘筱茂,刘茂林,等.刘茂林治疗抑郁症的临床经验[J].陕西中医2011,32(9)：1210-1211
[43]栾宁.脾胃枢机与抑郁症关系浅析[J].实用中医内科杂志2011,25(1)：46-47
[44]杨建,颜红.抑郁症从肺论治[J].天津中医药2011,28(3)：230-231
[45]刘紫凝,曹诗丹.浅议抑郁症从肺论治的中医理论基础[J].光明中医2009,24(3)：399-400
[46]谢磊,张鹏,罗瑞,等.基于“肾为元阳之本”探讨温补肾阳方治疗抑郁症[J].中华中医药杂志2011,26(5)：1130-1134
[47]李清亚,张松,祝杨,等.辨证论治抑郁症临床观察[J].中国中医药信息杂志2008,15(5)：75-76
[48]周启昌,李芳梅,刘琼,等.试论抑郁症的辨证论治[J].中国中医药现代远程教育2009,6(10)：1143-1144
[49]富文俊.从卫气营血辨证论治抑郁症的理论探讨[J].中国中医药现代远程教育2008,6(11)：1310-1312
[50]Sarris J, Panossian A, Schweitzer I, et al. Herbal medicine for depression, anxiety and insomnia:A review of psychopharmacology and clinical evidence[J]. Eur Neuropsychopharmacol,2011, Epub ahead of print.
[51]Dwyer AV, Whitten DL, Hawrelak JA,et al. Herbal medicines, other than St. John's Wort, in the treatment of depression:a systematic review[J]. Altern Med Rev,2011,16(1):40-49.
[52]孔庆梅,舒良,张鸿燕,等.巴戟天寡糖胶囊治疗抑郁症的临床疗效与安全性[J].中国临床药理学杂志,2011,27(3)：170-173.
[53]何成瑜.醒脑汤治疗中风后抑郁症150例临床观察[J].新中医2010,42(6)：64-66.
[54]王春香,陈桂莲,龙梅,等.解郁汤治疗产后抑郁症27例[J].中国实验方剂学杂志,2011,17(9)：292.
[55]韩辉,杨文明,韩明向,等.加减血府逐瘀汤治疗脑卒中后抑郁症的随机对照临床研究[J].中国新药与临床药理,2010,21(1)：86-88.
[56]李硕,孙书坤,温绍琴,等.疏肝健脾汤辅助治疗肝郁脾虚型抑郁症40例[J].山东医药,2010,50(3)：103.
[57]朱晨军,唐启盛,曲淼,等.安神定志丸治疗心胆气虚型抑郁症的临床疗效观察[J].中国实验方剂学杂志,2010,16(5)：206-208.
[58]Zhang HL. Treatment of depression based on differentiation of the Shaoyang Channels[J].J Tradit Chin Mod,2010,30(2):83-92.
[59]Wang Y, Fan R, Huang X, et al. Meta-analysis of the clinical effectiveness of traditional Chinese medicine formula Chaihu-Shugan-San in depression[J].J Ethnopharmacol,2011,12. [Epub ahead of print].
[60]龙伟芳,单志恒.解郁1号方治疗心脾两虚型抑郁症30例[J].新中医2010,42(3)：38-39.
[61]尚俊平.柴胡加龙骨牡蛎汤治疗老年抑郁症30例[J].甘肃中医2010,23(2)：47-48
[62]李文迅.电针对抑郁模型大鼠海马神经元凋亡的影响[J].中国医药信息杂志 2005,12：33-35
[63]符文彬,马瑞,刘健华,等.电针对抑郁症大鼠海马超微结构的影响.广州中医药大学学报2011,28(5)：495-498,563-564.
[64]陈理,王玲玲.通督调神针法对抑郁症大鼠海马Bax和bcl-2的影响.中医药学报2011,39(6)：85-88.
[65]Feng Y, Wang XY, Li SD, et al. Clinical research of acupuncture on malignant tumor patients for improving depression and sleep quality[J]. J Tradit Chin Med 2011,31(3):199-202.
[66]Zhang JB, Ren L, Sun Y, et al. Meta-analysis on acupuncture for treatment of depression in patients of poststroke[J]. Zhongguo Zhen Jiu 2009,29(7): 599-602.
[67]Xie YC, Li YH. Observation on therapeutic effect of acupuncture at Zhongwan (CV 12) and Si-guan points combined with reinforcing-reducing manipulation of respiration for treatment of depression[J]. Zhongguo Zhen Jiu 2009,29(7):521-524.
[68]Wang XJ, Wang LL, Qiao HF,et al. Observation on effective characteristics of acupuncture combined with medicine on depression of different syndrome types[J]. Zhongguo Zhen Jiu,2009 29(9):699-702.
[69]Wang XY, Li XY, Deng AJ, et al. Comparative study on abdominal acupuncture and western medicine for treatment of menopause depressive disorder[J]. Zhongguo Zhen Jiu 2010,30(11):913-917.
[70]李玉波.产后抑郁症中医病机治则及孕妇产期心理保健问题探讨[J].亚太传统医药,2011,7(10)：146-147.
[71]金季玲,赵珂冯,秋霞,等.中药联合心理疏导治疗围绝经期抑郁症临床研究[J].新中医,2011,43(7)：70-72.
[72]周秀芳,刘瑶,李燕,等.五输穴透刺结合心理疗法治疗抑郁症的疗效观察[J].辽宁中医杂志,2010,37(1)：151-152.
[73]金韬,汪琛,谭小林,等.音乐疗法辅助抗抑郁药治疗抑郁症的临床疗效观察[J].重庆医学,2011,40(17)：1703-1705.
[74]李林,姜云,徐金贵,等.五行音乐合中药治疗围绝经期抑郁症的临床观察[J].中华中医药杂志,2011,26(11)：2758-2760.
[75]李辉,朱天民.中医传统音乐疗法治疗糖尿病抑郁症临床研究[J].辽宁中医杂志,2011,8(5)：929-930.
[76]戴建国,陈琳,王中立,赵玉男,黄玉芳.助阳宁神方拮抗皮质酮诱导的海马功能重塑性损伤的作用[J].江苏医药2012,38(3)：252-255
[77]王雀良,潘集阳,刘亚平等.抑郁症动物模型的回顾与展望[J].广东医学,2011,7(32)：932-935.
[78]Voermier J B, Seligman M E. Effects of inescapable shock upon subsequent escape and avoidance responding[J]. J Comp Physiol,1967,63(1):28-33.
[79]Cryan JF, Mombereau C. In search of a depressed mouse:utility of models for studying depression-related behavior in genetically modified mice[J]. Mol Psychiatry,2004,9:326-357.
[80]秦琴,刘利学. 抑郁症动物模型概述及评价[J]. 实验动物科学,2010,1(27)：53-59.
[81]Katz R J, Roth K A, Carroll B J, et al. Acute and chronic stress effects on open field activity in the rat:Implications for a model of depression [J]. Neurosci Biobehav Rev,1981,5(2):247-251.
[82]Willner P. Validity, reliability and utility of the chronic mild stress model of depression:a 10 year review and evaluation[J]. Psychopharmacology(Bed),1997,134(4):319-329.
[83]陈湘,窦建卫,胡亚.抑郁症动物模型的应用及研究进展[J].中国组织工程研究与临床康复,208,28(12)：5521-5524.
[84]张飞龙,徐志伟,范礼斌等.社会失败应激致抑郁样行为动物模型的研究[J].军事医学2011,3(35)：193-196.
[85]Hua-Cheng YAN, Xiong CAO, Manas Das, et al. Behavioral animal models of depression[J]. Neurosci Bul,2010,26(4):327-337.
[86]Hennessy MB, Deak T, Schiml-Webb PA. Stress-induced sickness behaviors:an alternative hypothesis for responses during maternal separation[J]. Dev Psychobiol,2001,38(2):76-78.
[87]Porsolt RD, LePichon M, Jalfre M. Depression:a new animal model sensitive to antidepressant treatments [J]. Nature 1977,266:730-732.
[88]Steru L, Chermat R, Thierry B, et al. The tail suspension test:a new method for screening antidepressants in mice[J]. Psychopharmacology(Berl), 1985,85(3):367-370.
[89]昌俊华,库宝善.电刺激小鼠角膜诱发的不动状态一一种新的抗抑郁药物研究动物模型[J].北京医科大学学报,1990,22(5)：36-39.
[90]Dulawa SC, lien R. Recent advances in animal models of chronic antidepressant effects:the novelty-induced hypophagia test[J]. Neurosci Biobehav Rev,2005,29(4-5):771-783
[91]Deussing JM. Animal models of depression[J]. Drug Discov Today Dis Models, 2006,3 (4):375-383.
[92]McArthur R, Borsini F. Animal models of depression in drug discovery:a historical perspective[J]. Pharmacol Biochem Behav 2006,84(3):436-452.
[93]Burkard WP, Bonetri EP, Prada MD, et a.1 Pharmacol of ical profilermoclobemide, a short cting and reversible inhibitor of monoamine oxidase type A[J]. Pharmacol Exp Ther 1989,284(1):391-399.
[94]Pawlowski L, Mazela H. Effects of antidepressant drugs, selecrive noradrenaline or 5-hydroxytryptamine uptake inhibitors, on anpomorphine-induced hypothermia in mic e[J]. Psychopharmacology, 1986,88(2):240-246.
[95]赵玉男,戴建国,王中立等.长期皮质酮注射对C57BL-6N小鼠海马胶质纤维酸性蛋白水平的影响[J].中国病理生理杂志,2010,26(10)：2046.
[96]Gregus A, Wintink AJ, Davis AC, et al. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats[J]. Behav Brain Res,2005,156(1):105-114.
[97]乐洪波,马树华,程晓玲.药物诱导的抑郁症动物模型的应用与评价[J].国际精神病学杂志,2009,1(36)：33-35.
[98]Harkin A, Kelly JP, Leonard BE. A review of the relevance and validity of olfactory bulbectomy as a model of depression[J]. Clin Neurosci Res, 2003,3(4-5):253-262.
[99]Bondi M, Caretta A. Animal models of depression:olfactory lesions affect amygdala, subventricular zone, and aggression[J]. Neurobiol Dis, 2004,16(2):386-395.
[100]Dafer RM, Rao M, Shareef A, et al. Post-stroke depression[J]. Top Stroke Rehabil,2008,15(1):13-21.
[101]志华.抑郁症动物模型的研究进展[J].安徽中医,2008,2(29)：211-213.
[102]Galea LA, Wide JK, Barr AM. Estradiol alleviates depressive-like symptoms in a novel animal model of postpartum depression[J]. Behav Brain Res, 2001,122:1-9.
[103]Lesch K P. Gene-environment interaction and the genetics of depression [J]. J Psychiatry Neurosci,2004,29(3):174-184.
[104]Lopez Rubalcava C, Lucki L. Strain differences in the behavioural effects of antidepressant drugs in the rat forced swimming test[J]. Neuropsycho pharmacology,2000,22(2):191-199.
[105]Gomez F, Grauges P, Lopez-Calderon A, et al. Abnormalities of hypothalamic-pituitary-adrenal and hypothalamic-somatotrophic axes in Fawn-Hooded rats[J]. Eur Endocrinol 1999,141(3):290-296.
[106]Weiss JM, Cierpial MA, West CH. Selective breeding of rats for high and lowmotor activity in a swim test:toward a new animal model of depression[J]. Pharmcol Biochem Behav,1998,61(1):49-66.
[107]Chourbaji S, Gass P. Glucocorticoid receptor transgenic mice as models for depression[J]. Brain Res Rev 2008,57(2):554-560.
[108]Boyle MP, Kolber BJ, Vogt SK, et al. Forebrain glucocorticoid receptors modulate anxiety associated locomotor activation and adrenal responsiveness[J]. J Neurosci 2006,26(7):1971-978
[109]杨建宇,范竹雯,李彦知等. 抑郁症中医治疗概况[J].光明中医,2011,10(26)：2167-2168.
[110]吕嫒.心理疏导配合音乐疗法治疗产后抑郁症的效果分析[J].中国社区医师.医学专业,2011,31(13)：285.
[111]Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice:a primary screening test for antidepressants [J]. Arch Int Pharmacodyn Ther,1977, 229(2):327-336.
[112]Steru L, Chermat R, Thierry B, et al. The tail suspension test:a new methoc for screening antidepressants in mice [J]. Psycho-pharmacology (Berl), 1985,85(3):367-370.
[113]张金良,王宪波,曾辉.从中医学角度谈糖皮质激素副作用的药理机制[J].北京中医药,2010,29(4)：276-279.
[114]沈自尹,吴志军,于立华,等.淫羊藿总黄酮对皮质酮诱导免疫功能低下大鼠的保护作用及配伍研究[J].中国药理学通报,2007,23(8)：1061-1063.
[115]马清翠,于华芸,赵俭,等.附子、干姜、黄连、大黄对正常大鼠能量代谢的影响[J].山东中医药大学学报,2010,34(5)：379-380,390.
[116]Dranovsky A, Hen R. Hippocampal neurogenesis:regulation by stress and antidepressants[J]. Biol Psychiatry,2006,59(12):1136-1143.
[117]Sheline YI, Wang PW, Gado MH,et al. Hippocampal atrophy in recurrent major depression[J]. Proc Natl Acad Sci USA,1996,93 (9):3908-3913.
[118]徐林.抑郁症的神经可塑性机制[J].中南大学学报(医学版),2008,33(4)：326-330.
[119]Sairanen M,0'Leary OF, Knuuttila JE, et al. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat [J]. Neuroscience,2007,144 (1):368-374.
[120]Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders:A review and a Western blot study of synaptophysin, GAP-43 and the complexins [J]. Brain Res Bull,2001, 55 (5):569-578.
[121]ShaoY, McCarthyKD. Plasticity of astrocytes. Glia 1994,11:147-155.
[122]Barker AJ, Ullian EM. Astrocytes and synaptic plasticity [J]. Neurosci Entist 2010,16(1):40-50.
[123]Halassa MM, Haydon PG. Integrated brain circuits:astrocytic networks modulate neuronal activity and behavior[J]. Annu Rev Physiol.2010,2: 35-355.
[124]Costello DA, Claret M, Al-Qassab H, Plattner F, Irvine EE, Choudhury AI, Giese KP, Withers DJ, Pedarzani P.Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity[J].PloS One 2012,7(2):e31124.
[125]Liu R, Lei JX, Luo C, Lan X, Chi L, Deng P, Lei S, Ghribi 0, Liu QY. Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease [J].Neuro biol Dis.2012,45(3):902-912.
[126]李则挚,洪武,方贻儒.脑源性神经营养因子在抑郁症发作病理机制中的作用[J].上海交通大学学报(医学版),2010,30(6)：651-655.
[127]马长永,马春明GDNF在脑疾病中研究进展[J].医学信息,2008,21(8)：1472-1473.
[1]张柳、朱霞.60例脑梗死偏瘫并发抑郁症患者心理治疗的研究[J].中国现代养生2010,48(6)：40-41.
[2]范文涛和王倩.醒脑解郁方配合心理辅导治疗卒中后抑郁症30例临床观察[J].新中医2009,41(4)：62-63.
[3]周丽琴.脑卒中合并抑郁症的心理治疗观察[J].中国误诊学杂志 09,9(8)：1793
[4]毛顺.脑卒中后抑郁患者评估及心理干预[J].中国实用神经疾病杂志2009,12(20)：19-20.
[5]于楠.心理治疗联合药物治疗脑梗死后抑郁症[J].山西医药杂志2009,38(11)：1035-1036.
[6]乐杰.妇产科学[M].第6版.北京：人民卫生出版社,2005：240-241.
[7]艾维颖,高山凤,阚秀莲等.补血益气组方联合心理干预治疗产后抑郁症的临床研究[J].实用药物与临床2011,14(3)：196-198.
[8]李晨虎,沈文龙,饶顺等.团体人际心理治疗产后抑郁症的疗效观察[J].中国妇幼保健2009,24(30)：4231-2433.
[9]姚刚,余绍兰.心理社会干预联合药物治疗对产后抑郁症的疗效观察[J].中外医学研究2011,9(20)：8-9.
[10]黄超,罗昭平,方政华.药物联合音乐心理治疗产后抑郁症的疗效观察[J].医学信息2010,23(3)：636-637.
[11]陈书香,陈书芳,范银芬,等.早期心理干预对产后抑郁及儿童心理发育的近远期影响研究[J].中国妇幼保健2011,26(10)：1564-1566.
[12]李爱琴.对大学生抑郁症进行心理干预的几点建议[J]. 教育探索2009,(3)：113-114.
[13]林萍,姚爱华.心理治疗高职学生抑郁症40例案例分析[J].南方医科大学学报2010,30(7)：1760-1761.
[14]喻瑶.青少年抑郁症患者的团体人际心理治疗[J].医学与哲学(人文社会医学版)2011,32(3)：41-43.
[15]黄晓艳,王哲.氟西汀与其联合心理治疗对青少年抑郁症疗效比较[J].中国误诊学杂志2009,9(7)：1543
[16]朱记军,万清华,钱景华.氟西汀合并心理治疗对青少年抑郁症疗效的观察[J].中国民康医学2009,21(17)：2135-2136.
[17]太鑫,韩泰哲,滕丽萍等.针刺结合心理疗法治疗大学生抑郁症37例[J].中医药信息2010,27(4)：92-93.
[18]Mirabel-Sarron C. Evaluation of behavioral and cognitive therapy in depression [J]. Bull Acad Natl Med.2010,194(3):605-615.
[19]Negovanska V, Hergueta T, Guichart-Gomez E, et al. Beneficial effect of a cognitive behavioral and multidisciplinary program in Alzheimer Disease on spouse caregiver anxiety:French study ELM-MA[J]. Rev Neurol (Paris).2011, 167 (2):114-122.
[20]Jean L, Simard M,Wiederkehr S,et al. Efficacy of a cognitive training programme for mild cognitive impairment:results of a randomised controlled study[J]. Neuropsychol Rehabil,2010,20 (3):377-405.
[21]叶郁葱,邱娟红,冯燕.“三位一体”心理干预在老年抑郁症患者中的应用[J].现代临床护理2011,10(2)：18-20.
[22]唐思源,严良卉,蒋淑红.老年抑郁症门诊心理治疗的疗效观察[J].中华全科医学2009,7(1)：55-56.
[23]赫楠,李洪涛,马秀琴.老年抑郁症门诊心理治疗研究[J].中国实用医药2010,5(7)：242-243.
[24]闫加民.罗西汀合用心理行为干预治疗老年期抑郁症的疗效[J].中国健康心理学杂志2008,16(8)：926-927.
[25]孔凡贞,吴冠会,黄丽君,等。认知行为治疗对老年抑郁症疗效的研究[J].社区医学杂志2011,9(14)：13-14.
[26]Inoue K. Cognitive-behavioral therapy for treatment-resistant depression [J] Seishin Shinkeigaku Zasshi 2010,112(11):1097-1104.
[27]Crowe M, Whitehead L, Wilson L, et al. Disorder-specific psychosocial interventions for bipolar disorder-asystematic review of the evidence for mental health nursing practice[J]. Int J Nurs Stud.2010,47(7):896-908.
[28]张富松,符娟,潘苗[]心理社会干预对老年抑郁症患者社会功能及生活质量的影响[J].职业与健康,2011,27(10)：1124-1126.
[29]黄智前,黄吟,张惠,等。综合心理治疗联合药物治疗对老年抑郁症的疗效观察[J].实用老年医学2010,24(6)：510-512.
[30]吴毓敏,郭选贤,韩琼政.老年2型糖尿病合并抑郁症心理干预加抗抑郁药物治疗疗效分析[J].山东医药2009,49(29)：114
[31]万雪琴.舍曲林联合心理治疗对糖尿病伴抑郁患者生存质量的影响[J].江西医药2010,45(10)：1017-1018.
[32]杨杰.糖尿病患者治后抑郁的护理干预及效果研究[J].中国实用医药2011,6(5)：188-189.
[33]姜海芬.统心理干预对2型糖尿病伴抑郁症患者症状及生活质量的影响[J]中国健康心理学杂志2011,19(1)：34-36
[34]张英,李春花,李可心.心理干预对老年2型糖尿病合并抑郁症患者治疗的影响[J]. 中国实用医药2010,5(6)：170-171.
[35]高君,张英,刘力华.心理咨询技术对2型糖尿病合并抑郁患者病情控制的影响[J].吉林医学2010,31(34)：6181-6183.
[36]Okuyama T, Nakane Y, Endo C, et al. Mental health literacy in Japanese cancer patients:ability to recognize depression and preferences of treatments-comparison with Japanese lay public. Psychooncology 2007,16(9): 834-842.
[37]孔晓玲,魏爱萍.对恢复期乳腺癌抑郁患者心理干预的效果观察[J].临床医药实践2011,20(1)：56-57.
[38]景文.老年恶性肿瘤伴发抑郁症心理护理效果分析[J].中国误诊学杂志2011,11(8)：1794.
[39]庆玲.团体心理治疗对老年癌症住院患者抑郁症疗效的影响[J].中国老年学杂志2010,(30)：2048-2049.
[40]晓梅.心理干预治疗癌症患者抑郁症的系统评价[J].中国循证医学杂志2010,10(3)：352-355.
[41]张杰,唐亮.2005-2007年我院抗抑郁药应用分析[J].现代医学,2009,37(2)：162-163.
[2]Gronli J, Bramham C, Murison R, et al. Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper. Pharmacol Biochem Behav 2006,85:842-849
[3]Berton 0, Nestler EJ. New approaches to antidepressant drug discovery:beyond monoamines. Nature Rev Neurosci 2006,7:137-151
[4]薛瑞,张有志,邹莉波.快速起效抗抑郁药物的研究进展[J].中国药理学通报,2006,24(12)：1558-1561.
[5]楼剑书,杨晓春,方杰,等.免疫激活对抑郁症谷氨酸和五羟色胺系统的调节[J].中国药理学通报,2009,25(12)：1555-1558
[6]张敬军.星形胶质细胞的研究[J].中国药理学通报,2006,22(7)：788-791
[7]He F, Sun Y E. Glial cells more than support cell[J]? Int J Biochem Cell B iol,2007,39 (4):661-665.
[8]Kimelberg HK. The role of hypotheses in current research, illustrated by hypotheses on the possible role of astrocytes in energy metabolism and cerebral blood flow:from Newton to now [J]. J. Cereb. Blood Flow Metab,2004, 24:1235-1239
[9]Tekkok SB, Brown AM, Westenbrock R, et al. Transfer of glycogen-derived lactate from astrocytes to axons via specific monocarboxylate transporters supports mouse optic nerve activity. J. Neurosci. Res.2005,81:644-652
[10]Koudinov AR, Koudinova NV. Cholesterol's role in synapse formation[J]. Science,2002; 295(5563):2213
[11]Miller G. Society for neuroscience meeting:neurons get connected via glia[J]. Science,2003; 302:1323-1323
[12]Murai KK, Nguye LN, Irie F, et al. Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling[J]. Nat Neurosci,2002,6: 153-160
[13]Song HJ, Stevens CF, Gage FH. Neural Stem Cells from Adult Hippocampus Develop Essential Properties of Functional CNS Neurons[J]. Nat Neurosci, 2002,5 (5):438-445
[14]Williams SM, Diaz CM, Macnab LT, et al. Immunocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons[J]. Glia 2006,53:401-411
[15]Verrall L, Walker M, Rawlings N, et al. D-amino acid oxidase and serine racemase in human brain:normal distribution and altered expression in schizophrenia[J]. Eur. J. Neurosci.2007,26:1657-1669
[16]Czeh B, Simon M, Schmelting B, et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment[J]. Neuropsychopharmacology,2006,31:1616-1626.
[17]Si X, Miguel-Hidalgo JJ,O'Dwyer G, et al. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression[J]. Neuropsychopharmacology 2004,29:2088-2096
[18]Webster MJ,O'Grady J, Kleinman JE, et al. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia[J]. Neuroscience 2005,133:453-461
[19]Leventopoulos M, Ruedi-Bettschen D, Knuesel I, et al. Long-term effects of early life deprivation on brain glia in Fischer rats[J]. Brain Res,2007, 1142:119-126
[20]Gosselin RD, Gibney S,O'Malley D, et al. Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression[J]. Neuroscience 2009,159:915-925
[21]Czeh B, Simon M, Schmelting B, et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment[J]. Neuropsychopharmacology2006,31:1616-1626
[22]Banasr M, Chowdhury G. M, Terwi 11 iger R, et al. Glial pathology in an animal model of depression:reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole[J]. Mol. Psychiatry, e-pub ahead of print 30 September 2008; doi:10.1038/mp.2008.106.
[23]Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressivc-like behaviors. Biol. Psychiatry,2008,64:863-870
[24]陈红霞,张黎明,张有志,等.胍丁胺对慢性应激人鼠海马神经元和星形胶质细胞的影响[J].中国药理学通报,2009,25(1)：21-25
[24]Chen HX, Zhang LM, Zhang YZ,et al. Effect of agmatine on the neurons and astrocytes in hippocampus of chronically stressed rats[J]. Chin Pharmacol Bull,2009,25 (1):21-25
[25]Liu Q, Li B, Zhu HY, et al. Clomipramine treatment reversed the glial pathology in a chronic unpredictable stress-induced rat model of depression[J]. Eur Neuropsychopharmacol,2009,19:796-805
[26]Rose C. Effect of ammonia on astrocytic glutamate uptake/release mechanisms[J]. J Neurochem,2006,97:11-15
[27]Ozawa S. Role of glutamate transporters in excitatory synapses in cerebellar Purkinje cells[J]. Brain Nerve,2007,59:669F-676
[28]Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA. Reduced expression of glutamate transporters vGluTl, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression[J]. Neuropharmacology,2010,58(2):465-473
[29]郭坤萌,周唯.抑郁症辨证论治述要[J].山东中医杂志2011,30(2)：77-78
[30]鱼浚镛,田金洲.试述中医对抑郁症的认识[J].天津中医药2011,28(4)：343-345
[31]华燕.抑郁症的诊断及中医辨证论治[J].辽宁中医药大学学报2011,13(10)：17-18
[32]毕国伟,卢政男,江泳.抑郁症发病的基础病机之论阳气不足论[J].成都中医药大学学报2011,34(3)：88-90
[33]包祖晓,田青,陈宝君,钟宇峰,李黎.抑郁症与中医阳气亏虚证关系的探讨[J].浙江中医药大学学报2011,35(3)：466-467
[34]冼慧,清华.抑郁症的中医辨治[J].北京中医,2007,26(3)：136-137
[35]赵晶.抑郁症从脾论治[J].吉林中医药,2011,31(6)：506-507
[36]陈文铠,周玲,梅晓云,彭昌孝,李国春,黄云,陈文姬,彭计红.从临床流行病学调查探讨抑郁症中医病机规律[J].南京中医药大学学报2005,21(5)：273-276.
[37]张有为,谢忠礼.抑郁症中医病因病机探讨[J].中医学报2010,25(148)：435-436.
[38]张昶,谭程.抑郁症从奇经论治浅析[J].北京中医药2010,29(3)：196-198.
[39]姜林芳,方习红.王法德辨治抑郁症经验[J].中医杂志2010,51(6)：495,509.
[40]杨小青,张小玲.从中医“情志致病”探讨抑郁症成因[J].辽宁中医药大学学报2010,12(9)：87-88
[41]宋通贵,孙萍,张燕,等.中医辨证论治抑郁症的探讨[J].中国实用医药2009,4(25)：220-221
[42]杨耀峰,刘筱茂,刘茂林,等.刘茂林治疗抑郁症的临床经验[J].陕西中医2011,32(9)：1210-1211
[43]栾宁.脾胃枢机与抑郁症关系浅析[J].实用中医内科杂志2011,25(1)：46-47
[44]杨建,颜红.抑郁症从肺论治[J].天津中医药2011,28(3)：230-231
[45]刘紫凝,曹诗丹.浅议抑郁症从肺论治的中医理论基础[J].光明中医2009,24(3)：399-400
[46]谢磊,张鹏,罗瑞,等.基于“肾为元阳之本”探讨温补肾阳方治疗抑郁症[J].中华中医药杂志2011,26(5)：1130-1134
[47]李清亚,张松,祝杨,等.辨证论治抑郁症临床观察[J].中国中医药信息杂志2008,15(5)：75-76
[48]周启昌,李芳梅,刘琼,等.试论抑郁症的辨证论治[J].中国中医药现代远程教育2009,6(10)：1143-1144
[49]富文俊.从卫气营血辨证论治抑郁症的理论探讨[J].中国中医药现代远程教育2008,6(11)：1310-1312
[50]Sarris J, Panossian A, Schweitzer I, et al. Herbal medicine for depression, anxiety and insomnia:A review of psychopharmacology and clinical evidence[J]. Eur Neuropsychopharmacol,2011, Epub ahead of print.
[51]Dwyer AV, Whitten DL, Hawrelak JA,et al. Herbal medicines, other than St. John's Wort, in the treatment of depression:a systematic review[J]. Altern Med Rev,2011,16(1):40-49.
[52]孔庆梅,舒良,张鸿燕,等.巴戟天寡糖胶囊治疗抑郁症的临床疗效与安全性[J].中国临床药理学杂志,2011,27(3)：170-173.
[53]何成瑜.醒脑汤治疗中风后抑郁症150例临床观察[J].新中医2010,42(6)：64-66.
[54]王春香,陈桂莲,龙梅,等.解郁汤治疗产后抑郁症27例[J].中国实验方剂学杂志,2011,17(9)：292.
[55]韩辉,杨文明,韩明向,等.加减血府逐瘀汤治疗脑卒中后抑郁症的随机对照临床研究[J].中国新药与临床药理,2010,21(1)：86-88.
[56]李硕,孙书坤,温绍琴,等.疏肝健脾汤辅助治疗肝郁脾虚型抑郁症40例[J].山东医药,2010,50(3)：103.
[57]朱晨军,唐启盛,曲淼,等.安神定志丸治疗心胆气虚型抑郁症的临床疗效观察[J].中国实验方剂学杂志,2010,16(5)：206-208.
[58]Zhang HL. Treatment of depression based on differentiation of the Shaoyang Channels[J].J Tradit Chin Mod,2010,30(2):83-92.
[59]Wang Y, Fan R, Huang X, et al. Meta-analysis of the clinical effectiveness of traditional Chinese medicine formula Chaihu-Shugan-San in depression[J].J Ethnopharmacol,2011,12. [Epub ahead of print].
[60]龙伟芳,单志恒.解郁1号方治疗心脾两虚型抑郁症30例[J].新中医2010,42(3)：38-39.
[61]尚俊平.柴胡加龙骨牡蛎汤治疗老年抑郁症30例[J].甘肃中医2010,23(2)：47-48
[62]李文迅.电针对抑郁模型大鼠海马神经元凋亡的影响[J].中国医药信息杂志 2005,12：33-35
[63]符文彬,马瑞,刘健华,等.电针对抑郁症大鼠海马超微结构的影响.广州中医药大学学报2011,28(5)：495-498,563-564.
[64]陈理,王玲玲.通督调神针法对抑郁症大鼠海马Bax和bcl-2的影响.中医药学报2011,39(6)：85-88.
[65]Feng Y, Wang XY, Li SD, et al. Clinical research of acupuncture on malignant tumor patients for improving depression and sleep quality[J]. J Tradit Chin Med 2011,31(3):199-202.
[66]Zhang JB, Ren L, Sun Y, et al. Meta-analysis on acupuncture for treatment of depression in patients of poststroke[J]. Zhongguo Zhen Jiu 2009,29(7): 599-602.
[67]Xie YC, Li YH. Observation on therapeutic effect of acupuncture at Zhongwan (CV 12) and Si-guan points combined with reinforcing-reducing manipulation of respiration for treatment of depression[J]. Zhongguo Zhen Jiu 2009,29(7):521-524.
[68]Wang XJ, Wang LL, Qiao HF,et al. Observation on effective characteristics of acupuncture combined with medicine on depression of different syndrome types[J]. Zhongguo Zhen Jiu,2009 29(9):699-702.
[69]Wang XY, Li XY, Deng AJ, et al. Comparative study on abdominal acupuncture and western medicine for treatment of menopause depressive disorder[J]. Zhongguo Zhen Jiu 2010,30(11):913-917.
[70]李玉波.产后抑郁症中医病机治则及孕妇产期心理保健问题探讨[J].亚太传统医药,2011,7(10)：146-147.
[71]金季玲,赵珂冯,秋霞,等.中药联合心理疏导治疗围绝经期抑郁症临床研究[J].新中医,2011,43(7)：70-72.
[72]周秀芳,刘瑶,李燕,等.五输穴透刺结合心理疗法治疗抑郁症的疗效观察[J].辽宁中医杂志,2010,37(1)：151-152.
[73]金韬,汪琛,谭小林,等.音乐疗法辅助抗抑郁药治疗抑郁症的临床疗效观察[J].重庆医学,2011,40(17)：1703-1705.
[74]李林,姜云,徐金贵,等.五行音乐合中药治疗围绝经期抑郁症的临床观察[J].中华中医药杂志,2011,26(11)：2758-2760.
[75]李辉,朱天民.中医传统音乐疗法治疗糖尿病抑郁症临床研究[J].辽宁中医杂志,2011,8(5)：929-930.
[76]戴建国,陈琳,王中立,赵玉男,黄玉芳.助阳宁神方拮抗皮质酮诱导的海马功能重塑性损伤的作用[J].江苏医药2012,38(3)：252-255
[77]王雀良,潘集阳,刘亚平等.抑郁症动物模型的回顾与展望[J].广东医学,2011,7(32)：932-935.
[78]Voermier J B, Seligman M E. Effects of inescapable shock upon subsequent escape and avoidance responding[J]. J Comp Physiol,1967,63(1):28-33.
[79]Cryan JF, Mombereau C. In search of a depressed mouse:utility of models for studying depression-related behavior in genetically modified mice[J]. Mol Psychiatry,2004,9:326-357.
[80]秦琴,刘利学. 抑郁症动物模型概述及评价[J]. 实验动物科学,2010,1(27)：53-59.
[81]Katz R J, Roth K A, Carroll B J, et al. Acute and chronic stress effects on open field activity in the rat:Implications for a model of depression [J]. Neurosci Biobehav Rev,1981,5(2):247-251.
[82]Willner P. Validity, reliability and utility of the chronic mild stress model of depression:a 10 year review and evaluation[J]. Psychopharmacology(Bed),1997,134(4):319-329.
[83]陈湘,窦建卫,胡亚.抑郁症动物模型的应用及研究进展[J].中国组织工程研究与临床康复,208,28(12)：5521-5524.
[84]张飞龙,徐志伟,范礼斌等.社会失败应激致抑郁样行为动物模型的研究[J].军事医学2011,3(35)：193-196.
[85]Hua-Cheng YAN, Xiong CAO, Manas Das, et al. Behavioral animal models of depression[J]. Neurosci Bul,2010,26(4):327-337.
[86]Hennessy MB, Deak T, Schiml-Webb PA. Stress-induced sickness behaviors:an alternative hypothesis for responses during maternal separation[J]. Dev Psychobiol,2001,38(2):76-78.
[87]Porsolt RD, LePichon M, Jalfre M. Depression:a new animal model sensitive to antidepressant treatments [J]. Nature 1977,266:730-732.
[88]Steru L, Chermat R, Thierry B, et al. The tail suspension test:a new method for screening antidepressants in mice[J]. Psychopharmacology(Berl), 1985,85(3):367-370.
[89]昌俊华,库宝善.电刺激小鼠角膜诱发的不动状态一一种新的抗抑郁药物研究动物模型[J].北京医科大学学报,1990,22(5)：36-39.
[90]Dulawa SC, lien R. Recent advances in animal models of chronic antidepressant effects:the novelty-induced hypophagia test[J]. Neurosci Biobehav Rev,2005,29(4-5):771-783
[91]Deussing JM. Animal models of depression[J]. Drug Discov Today Dis Models, 2006,3 (4):375-383.
[92]McArthur R, Borsini F. Animal models of depression in drug discovery:a historical perspective[J]. Pharmacol Biochem Behav 2006,84(3):436-452.
[93]Burkard WP, Bonetri EP, Prada MD, et a.1 Pharmacol of ical profilermoclobemide, a short cting and reversible inhibitor of monoamine oxidase type A[J]. Pharmacol Exp Ther 1989,284(1):391-399.
[94]Pawlowski L, Mazela H. Effects of antidepressant drugs, selecrive noradrenaline or 5-hydroxytryptamine uptake inhibitors, on anpomorphine-induced hypothermia in mic e[J]. Psychopharmacology, 1986,88(2):240-246.
[95]赵玉男,戴建国,王中立等.长期皮质酮注射对C57BL-6N小鼠海马胶质纤维酸性蛋白水平的影响[J].中国病理生理杂志,2010,26(10)：2046.
[96]Gregus A, Wintink AJ, Davis AC, et al. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats[J]. Behav Brain Res,2005,156(1):105-114.
[97]乐洪波,马树华,程晓玲.药物诱导的抑郁症动物模型的应用与评价[J].国际精神病学杂志,2009,1(36)：33-35.
[98]Harkin A, Kelly JP, Leonard BE. A review of the relevance and validity of olfactory bulbectomy as a model of depression[J]. Clin Neurosci Res, 2003,3(4-5):253-262.
[99]Bondi M, Caretta A. Animal models of depression:olfactory lesions affect amygdala, subventricular zone, and aggression[J]. Neurobiol Dis, 2004,16(2):386-395.
[100]Dafer RM, Rao M, Shareef A, et al. Post-stroke depression[J]. Top Stroke Rehabil,2008,15(1):13-21.
[101]志华.抑郁症动物模型的研究进展[J].安徽中医,2008,2(29)：211-213.
[102]Galea LA, Wide JK, Barr AM. Estradiol alleviates depressive-like symptoms in a novel animal model of postpartum depression[J]. Behav Brain Res, 2001,122:1-9.
[103]Lesch K P. Gene-environment interaction and the genetics of depression [J]. J Psychiatry Neurosci,2004,29(3):174-184.
[104]Lopez Rubalcava C, Lucki L. Strain differences in the behavioural effects of antidepressant drugs in the rat forced swimming test[J]. Neuropsycho pharmacology,2000,22(2):191-199.
[105]Gomez F, Grauges P, Lopez-Calderon A, et al. Abnormalities of hypothalamic-pituitary-adrenal and hypothalamic-somatotrophic axes in Fawn-Hooded rats[J]. Eur Endocrinol 1999,141(3):290-296.
[106]Weiss JM, Cierpial MA, West CH. Selective breeding of rats for high and lowmotor activity in a swim test:toward a new animal model of depression[J]. Pharmcol Biochem Behav,1998,61(1):49-66.
[107]Chourbaji S, Gass P. Glucocorticoid receptor transgenic mice as models for depression[J]. Brain Res Rev 2008,57(2):554-560.
[108]Boyle MP, Kolber BJ, Vogt SK, et al. Forebrain glucocorticoid receptors modulate anxiety associated locomotor activation and adrenal responsiveness[J]. J Neurosci 2006,26(7):1971-978
[109]杨建宇,范竹雯,李彦知等. 抑郁症中医治疗概况[J].光明中医,2011,10(26)：2167-2168.
[110]吕嫒.心理疏导配合音乐疗法治疗产后抑郁症的效果分析[J].中国社区医师.医学专业,2011,31(13)：285.
[111]Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice:a primary screening test for antidepressants [J]. Arch Int Pharmacodyn Ther,1977, 229(2):327-336.
[112]Steru L, Chermat R, Thierry B, et al. The tail suspension test:a new methoc for screening antidepressants in mice [J]. Psycho-pharmacology (Berl), 1985,85(3):367-370.
[113]张金良,王宪波,曾辉.从中医学角度谈糖皮质激素副作用的药理机制[J].北京中医药,2010,29(4)：276-279.
[114]沈自尹,吴志军,于立华,等.淫羊藿总黄酮对皮质酮诱导免疫功能低下大鼠的保护作用及配伍研究[J].中国药理学通报,2007,23(8)：1061-1063.
[115]马清翠,于华芸,赵俭,等.附子、干姜、黄连、大黄对正常大鼠能量代谢的影响[J].山东中医药大学学报,2010,34(5)：379-380,390.
[116]Dranovsky A, Hen R. Hippocampal neurogenesis:regulation by stress and antidepressants[J]. Biol Psychiatry,2006,59(12):1136-1143.
[117]Sheline YI, Wang PW, Gado MH,et al. Hippocampal atrophy in recurrent major depression[J]. Proc Natl Acad Sci USA,1996,93 (9):3908-3913.
[118]徐林.抑郁症的神经可塑性机制[J].中南大学学报(医学版),2008,33(4)：326-330.
[119]Sairanen M,0'Leary OF, Knuuttila JE, et al. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat [J]. Neuroscience,2007,144 (1):368-374.
[120]Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders:A review and a Western blot study of synaptophysin, GAP-43 and the complexins [J]. Brain Res Bull,2001, 55 (5):569-578.
[121]ShaoY, McCarthyKD. Plasticity of astrocytes. Glia 1994,11:147-155.
[122]Barker AJ, Ullian EM. Astrocytes and synaptic plasticity [J]. Neurosci Entist 2010,16(1):40-50.
[123]Halassa MM, Haydon PG. Integrated brain circuits:astrocytic networks modulate neuronal activity and behavior[J]. Annu Rev Physiol.2010,2: 35-355.
[124]Costello DA, Claret M, Al-Qassab H, Plattner F, Irvine EE, Choudhury AI, Giese KP, Withers DJ, Pedarzani P.Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity[J].PloS One 2012,7(2):e31124.
[125]Liu R, Lei JX, Luo C, Lan X, Chi L, Deng P, Lei S, Ghribi 0, Liu QY. Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease [J].Neuro biol Dis.2012,45(3):902-912.
[126]李则挚,洪武,方贻儒.脑源性神经营养因子在抑郁症发作病理机制中的作用[J].上海交通大学学报(医学版),2010,30(6)：651-655.
[127]马长永,马春明GDNF在脑疾病中研究进展[J].医学信息,2008,21(8)：1472-1473.
[1]张柳、朱霞.60例脑梗死偏瘫并发抑郁症患者心理治疗的研究[J].中国现代养生2010,48(6)：40-41.
[2]范文涛和王倩.醒脑解郁方配合心理辅导治疗卒中后抑郁症30例临床观察[J].新中医2009,41(4)：62-63.
[3]周丽琴.脑卒中合并抑郁症的心理治疗观察[J].中国误诊学杂志 09,9(8)：1793
[4]毛顺.脑卒中后抑郁患者评估及心理干预[J].中国实用神经疾病杂志2009,12(20)：19-20.
[5]于楠.心理治疗联合药物治疗脑梗死后抑郁症[J].山西医药杂志2009,38(11)：1035-1036.
[6]乐杰.妇产科学[M].第6版.北京：人民卫生出版社,2005：240-241.
[7]艾维颖,高山凤,阚秀莲等.补血益气组方联合心理干预治疗产后抑郁症的临床研究[J].实用药物与临床2011,14(3)：196-198.
[8]李晨虎,沈文龙,饶顺等.团体人际心理治疗产后抑郁症的疗效观察[J].中国妇幼保健2009,24(30)：4231-2433.
[9]姚刚,余绍兰.心理社会干预联合药物治疗对产后抑郁症的疗效观察[J].中外医学研究2011,9(20)：8-9.
[10]黄超,罗昭平,方政华.药物联合音乐心理治疗产后抑郁症的疗效观察[J].医学信息2010,23(3)：636-637.
[11]陈书香,陈书芳,范银芬,等.早期心理干预对产后抑郁及儿童心理发育的近远期影响研究[J].中国妇幼保健2011,26(10)：1564-1566.
[12]李爱琴.对大学生抑郁症进行心理干预的几点建议[J]. 教育探索2009,(3)：113-114.
[13]林萍,姚爱华.心理治疗高职学生抑郁症40例案例分析[J].南方医科大学学报2010,30(7)：1760-1761.
[14]喻瑶.青少年抑郁症患者的团体人际心理治疗[J].医学与哲学(人文社会医学版)2011,32(3)：41-43.
[15]黄晓艳,王哲.氟西汀与其联合心理治疗对青少年抑郁症疗效比较[J].中国误诊学杂志2009,9(7)：1543
[16]朱记军,万清华,钱景华.氟西汀合并心理治疗对青少年抑郁症疗效的观察[J].中国民康医学2009,21(17)：2135-2136.
[17]太鑫,韩泰哲,滕丽萍等.针刺结合心理疗法治疗大学生抑郁症37例[J].中医药信息2010,27(4)：92-93.
[18]Mirabel-Sarron C. Evaluation of behavioral and cognitive therapy in depression [J]. Bull Acad Natl Med.2010,194(3):605-615.
[19]Negovanska V, Hergueta T, Guichart-Gomez E, et al. Beneficial effect of a cognitive behavioral and multidisciplinary program in Alzheimer Disease on spouse caregiver anxiety:French study ELM-MA[J]. Rev Neurol (Paris).2011, 167 (2):114-122.
[20]Jean L, Simard M,Wiederkehr S,et al. Efficacy of a cognitive training programme for mild cognitive impairment:results of a randomised controlled study[J]. Neuropsychol Rehabil,2010,20 (3):377-405.
[21]叶郁葱,邱娟红,冯燕.“三位一体”心理干预在老年抑郁症患者中的应用[J].现代临床护理2011,10(2)：18-20.
[22]唐思源,严良卉,蒋淑红.老年抑郁症门诊心理治疗的疗效观察[J].中华全科医学2009,7(1)：55-56.
[23]赫楠,李洪涛,马秀琴.老年抑郁症门诊心理治疗研究[J].中国实用医药2010,5(7)：242-243.
[24]闫加民.罗西汀合用心理行为干预治疗老年期抑郁症的疗效[J].中国健康心理学杂志2008,16(8)：926-927.
[25]孔凡贞,吴冠会,黄丽君,等。认知行为治疗对老年抑郁症疗效的研究[J].社区医学杂志2011,9(14)：13-14.
[26]Inoue K. Cognitive-behavioral therapy for treatment-resistant depression [J] Seishin Shinkeigaku Zasshi 2010,112(11):1097-1104.
[27]Crowe M, Whitehead L, Wilson L, et al. Disorder-specific psychosocial interventions for bipolar disorder-asystematic review of the evidence for mental health nursing practice[J]. Int J Nurs Stud.2010,47(7):896-908.
[28]张富松,符娟,潘苗[]心理社会干预对老年抑郁症患者社会功能及生活质量的影响[J].职业与健康,2011,27(10)：1124-1126.
[29]黄智前,黄吟,张惠,等。综合心理治疗联合药物治疗对老年抑郁症的疗效观察[J].实用老年医学2010,24(6)：510-512.
[30]吴毓敏,郭选贤,韩琼政.老年2型糖尿病合并抑郁症心理干预加抗抑郁药物治疗疗效分析[J].山东医药2009,49(29)：114
[31]万雪琴.舍曲林联合心理治疗对糖尿病伴抑郁患者生存质量的影响[J].江西医药2010,45(10)：1017-1018.
[32]杨杰.糖尿病患者治后抑郁的护理干预及效果研究[J].中国实用医药2011,6(5)：188-189.
[33]姜海芬.统心理干预对2型糖尿病伴抑郁症患者症状及生活质量的影响[J]中国健康心理学杂志2011,19(1)：34-36
[34]张英,李春花,李可心.心理干预对老年2型糖尿病合并抑郁症患者治疗的影响[J]. 中国实用医药2010,5(6)：170-171.
[35]高君,张英,刘力华.心理咨询技术对2型糖尿病合并抑郁患者病情控制的影响[J].吉林医学2010,31(34)：6181-6183.
[36]Okuyama T, Nakane Y, Endo C, et al. Mental health literacy in Japanese cancer patients:ability to recognize depression and preferences of treatments-comparison with Japanese lay public. Psychooncology 2007,16(9): 834-842.
[37]孔晓玲,魏爱萍.对恢复期乳腺癌抑郁患者心理干预的效果观察[J].临床医药实践2011,20(1)：56-57.
[38]景文.老年恶性肿瘤伴发抑郁症心理护理效果分析[J].中国误诊学杂志2011,11(8)：1794.
[39]庆玲.团体心理治疗对老年癌症住院患者抑郁症疗效的影响[J].中国老年学杂志2010,(30)：2048-2049.
[40]晓梅.心理干预治疗癌症患者抑郁症的系统评价[J].中国循证医学杂志2010,10(3)：352-355.
[41]张杰,唐亮.2005-2007年我院抗抑郁药应用分析[J].现代医学,2009,37(2)：162-163.